183430-28-6 Usage
General Description
3-Carbamimidoylmethyl-benzoic acid is a chemical compound with the molecular formula C10H10N2O2. This organic compound contains a carboxylic acid and a carbamimidoyl group attached to a benzene ring. It is commonly used in organic synthesis and pharmaceutical research due to its potential as a building block for drug development. The compound is also known for its anti-inflammatory and analgesic properties, making it a potential candidate for the development of new pharmaceutical drugs. Additionally, it is used as a reagent in organic chemistry reactions and is an important intermediate in the synthesis of various bioactive compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 183430-28-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,4,3 and 0 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 183430-28:
(8*1)+(7*8)+(6*3)+(5*4)+(4*3)+(3*0)+(2*2)+(1*8)=126
126 % 10 = 6
So 183430-28-6 is a valid CAS Registry Number.
183430-28-6Relevant articles and documents
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design
Chand, Pooran,Babu, Yarlagadda S.,Bantia, Shanta,Chu, Naiming,Cole, L. Brent,Kotian, Pravin L.,Laver, W. Graeme,Montgomery, John A.,Pathak, Ved P.,Petty, Sandra L.,Shrout, David P.,Walsh, David A.,Walsh, Gerald M.
, p. 4030 - 4052 (2007/10/03)
A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4- (acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10-6 M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase in a manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.
